Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2005

01.06.2005 | Original Article

Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer?

verfasst von: Yu-Chen Chang, Tzu-Chen Yen, Koon-Kwan Ng, Lai-Chu See, Chyong-Huey Lai, Ting-Chang Chang, Chien-Sheng Tsai, Ji-Hong Hong, Swei Hsueh, Hung-Hsueh Chou

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Compared with computed tomography (CT) and magnetic resonance imaging (MRI), positron emission tomography (PET) may have additional value in the assessment of primary and recurrent cervical cancer. However, the degree of tumour uptake of 18F-2-fluoro-2-deoxy-d-glucose (FDG) uptake is sometimes influenced by diabetes mellitus (DM). Therefore, we conducted this prospective study to compare the diagnostic ability of FDG-PET in patients with cervical cancer complicated by DM and those without DM.

Methods

Patients with untreated locally advanced primary or clinically curable recurrent cervical carcinoma were enrolled. Both FDG-PET and MRI/CT scans were performed within 2 weeks. Patients were categorised into the following groups: hyperglycaemic DM (fasting blood sugar >126 mg/dl), euglycaemic DM and non-DM. The lesions were confirmed histologically or by clinical follow-up. The receiver operating characteristic curve method, with calculation of the area under the curve (AUC), was used to evaluate the discriminative power.

Results

From February 2001 to January 2003, 219 patients (75 with primary and 144 with recurrent cervical cancer) were eligible for analysis. Sixteen had hyperglycaemic DM, 12 had euglycaemic DM and 191 were in the non-DM group. The diagnostic power of PET in the hyperglycaemic DM, euglycaemic DM and non-DM groups did not differ significantly with regard to the identification of either metastatic lesions (AUC, 0.967/0.947/0.925, P>0.05) or primary tumours/local recurrence (AUC, 0.950/0.938/0.979, P>0.05). Considering all DM patients, PET showed a significantly higher detection power than MRI/CT scans in respect of metastatic lesions (AUC=0.956 vs 0.824, P=0.012).

Conclusion

In comparison with its accuracy in non-DM patients, the accuracy of PET in cervical cancer patients with mild to moderate DM was not significantly reduced.
Literatur
1.
Department of Health, the Executive Yuan. Cancer registry annual report in Taiwan area, Department of Health, Executive Yuan, ROC, 2003.
2.
Yen TC, Ng KK, Ma SY, Chou HH, Tsai CS, Hsueh S, et al. Value of dual-phase 2-fluoro-2-deoxy-D-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003;21:3651–8.
3.
Tsai CC, Tsai CS, Ng KK, Lai CH, Hsueh S, Kao PF, et al. The impact of image fusion in resolving discrepant findings between FDG-PET and MRI/CT in patients with gynaecological cancers. Eur J Nucl Med Mol Imaging 2003;30:1674–83.
4.
Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed [18F]-2-fluoro-2-deoxy-glucose positron emission tomography for detection of para-aortic lymph node metastases in cervical cancer patients. J Nucl Med 2003;44:1775–83.PubMed
5.
Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al. [18F]-2-fluoro-2-deoxy-D-glucose uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004;45:22–9.
6.
Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, et al. Restaging of recurrent cervical cancer with dual-phase positron emission tomography. Cancer 2004;100:544–52.PubMed
7.
Tsai CS, Chang TC, Lai CH, Tsai CC, Ng KK, Hsueh S, et al. A preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes shown on MRI/CT images. Int J Radiat Oncol Biol Phys 2004;58:1506–12.
8.
Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998;39:1030–3.PubMed
9.
Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997;24:678–82.CrossRefPubMed
10.
Dave NN, Walia R, Shor M, Ali A. Effect of hyperglycemia on tumoral uptake of F-18 FDG. Clin Nucl Med 2002;27:682–3.
11.
Crippa F, Gavazzi C, Bozzetti F, Chiesa C, Pascali C, Bogni A, et al. The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinoma. Tumori 1997;83:748–52.
12.
Kubota K, Kubota R, Yamada S, Tada M, Takahashi T, Iwata R. Re-evaluation of myocardial FDG uptake in hyperglycemia. J Nucl Med 1996;37:1713–7.
13.
Peters AL, Schriger DL. The new diagnostic criteria for diabetes: the impact on management of diabetes and macrovascular risk factors. Am J Med 1998;105:15S–9S.
14.
Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycemia: the current status, definition and intervention. Diabet Med 2002;19:708–23.CrossRefPubMed
15.
Anzai Y, Carroll WR, Quint DJ, Bradford CR, Minoshima S, Wolf GT, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-(F-18)fluoro-D-glucose PET and MR imaging diagnosis. Radiology 1996;200:135–41.
16.
Hanley JA, McNeil BJ. A method of comparing the areas under a receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839–43.PubMed
17.
Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med 1993;34:1–6.
18.
Gorenberg M, Hallett WA, O’Doherty MJ. Does diabetes affect [18F]FDG standardized uptake values in lung cancer? Eur J Nucl Med Mol Imaging 2002;29:1324–7.
19.
Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hikosaka K, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumors and inflammatory lesions. Eur J Nucl Med 2001;28:730–5.
20.
Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology 1992;183:643–7.
21.
Langen KJ, Braun U, Rota Kops E, Herzog H, Kuwert T, Nebeling B, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinoma. J Nucl Med 1993;34:355–9.
22.
Torizuka T, Clavo AC, Wahl RL. Effects of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. J Nucl Med 1997;38:382–6.
23.
James DE. Targeting of the insulin-regulatable glucose transporter (GLUT-4). Biochem Soc Trans 1994;22:668–70.
Metadaten
Titel
Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer?
verfasst von
Yu-Chen Chang
Tzu-Chen Yen
Koon-Kwan Ng
Lai-Chu See
Chyong-Huey Lai
Ting-Chang Chang
Chien-Sheng Tsai
Ji-Hong Hong
Swei Hsueh
Hung-Hsueh Chou
Publikationsdatum
01.06.2005
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2005
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-004-1744-1

Weitere Artikel der Ausgabe 6/2005

European Journal of Nuclear Medicine and Molecular Imaging 6/2005 Zur Ausgabe

Original Article

99mTc-sestamibi thyroid uptake in euthyroid individuals and in patients with autoimmune thyroid disease

Original Article

[18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors

Original Article

Extension of myocardial necrosis differently affects MIBG retention in heart failure caused by ischaemic heart disease or by dilated cardiomyopathy

Molecular Imaging

The effect of citalopram hydrobromide on 5-HT2A receptors in the impulsive–aggressive dog, as measured with 123I-5-I-R91150 SPECT

Editorial

Sentinel node biopsy and selective lymph node clearance—impact on regional control and survival in breast cancer and melanoma

Original Article

In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer